MedPath

Effect of Dashmoola Katutrayadi Syrup in the management of Respiratory Allergies in Childre

Phase 3
Conditions
Health Condition 1: J069- Acute upper respiratory infection,unspecified
Registration Number
CTRI/2024/02/062324
Lead Sponsor
O ANY
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.Children having cardinal features of respiratory allergy

2.History of at least three episodes in last one year

3.Age group 6-12 years

Exclusion Criteria

1.Severe and complicated cases of respiratory allergies requiring hospitalization

2.Diagnosed case of Tuberculosis, Plural effusion, Emphysema, Lung abscess, Bronchiectasis, Pleurisy, Nasal polyps, Congenital lung/cardiac anomalies

3.Chronic debilitating diseases

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1.Change in Serum IgETimepoint: 8 weeks
Secondary Outcome Measures
NameTimeMethod
1.Change in peak expiratory flow rate (PEFR) <br/ ><br>2.Change in CBC, ESR, TEC <br/ ><br>3.Change in Morbidity score <br/ ><br>4.Change in quality of life <br/ ><br>Timepoint: 8 Weeks
© Copyright 2025. All Rights Reserved by MedPath